Asciminib single agent

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

17 competitors in Chronic Myelogenous Leukemia

#DrugCompanyPhaseTrials

1

Gleevec

Novartis

Approved

392

Tasigna

AAzurity Pharmaceuticals

Approved

173

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

124

Bosulif

PPrism Pharmaceuticals

Approved

55

Tukysa

Pfizer

Approved

—6

Depakote

AbbVie

Approved

—7

Jakafi

Incyte

Approved

—8

Scemblix

Novartis

Phase 3

59

Nizoral

WWim Janssens

Approved

—10

Nerlynx

PPuma Biotechnology, Inc.

Approved

—Show 8 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Chronic Myelogenous Leukemia2 trials

A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation

Recruiting·Novartis·Phase 2·NCT07354074·50 enrolled

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment

Recruiting·Novartis·Approved·NCT04877522·347 enrolled

Details

Drug Info

Related News